Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,882,785
  • Shares Outstanding, K 118,638
  • Annual Sales, $ 196,540 K
  • Annual Income, $ -140,040 K
  • EBIT $ -128 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.48
  • Price/Sales 9.91
  • Price/Cash Flow N/A
  • Price/Book 12.20

Options Overview Details

View History
  • Implied Volatility 73.00% ( -12.47%)
  • Historical Volatility 88.51%
  • IV Percentile 6%
  • IV Rank 19.05%
  • IV High 177.18% on 07/18/24
  • IV Low 48.49% on 10/09/24
  • Put/Call Vol Ratio 0.24
  • Today's Volume 865
  • Volume Avg (30-Day) 1,179
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 22,395
  • Open Int (30-Day) 17,869

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.22
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +46.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.75 +41.28%
on 02/25/25
17.70 -6.21%
on 03/17/25
+3.61 (+27.79%)
since 02/19/25
3-Month
11.13 +49.15%
on 02/11/25
17.70 -6.21%
on 03/17/25
+2.49 (+17.65%)
since 12/19/24
52-Week
6.99 +137.48%
on 06/10/24
17.70 -6.21%
on 03/17/25
+6.74 (+68.36%)
since 03/19/24

Most Recent Stories

More News
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ARQT : 16.60 (+4.60%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 16.60 (+4.60%)
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

ARQT : 16.60 (+4.60%)
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 

ARQT : 16.60 (+4.60%)
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally

Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.

ARQT : 16.60 (+4.60%)
VTI : 279.41 (+1.14%)
IWM : 206.37 (+1.56%)
XBI : 87.46 (+1.50%)
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ARQT : 16.60 (+4.60%)
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

ARQT : 16.60 (+4.60%)
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

ARQT : 16.60 (+4.60%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 16.60 (+4.60%)
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

ARQT : 16.60 (+4.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 18.22
2nd Resistance Point 17.53
1st Resistance Point 17.07
Last Price 16.60
1st Support Level 15.92
2nd Support Level 15.23
3rd Support Level 14.77

See More

52-Week High 17.70
Last Price 16.60
Fibonacci 61.8% 13.61
Fibonacci 50% 12.35
Fibonacci 38.2% 11.08
52-Week Low 6.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar